Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
暂无分享,去创建一个
C. Rudin | R. Govindan | D. Carbone | J. Wolf | D. Morgensztern | A. Dowlati | B. Besse | A. Farago | N. Ready | C. Hann | S. Le Moulec | B. Glisson | L. Greillier | S. Yalamanchili | R. Santana-Davila | S. Lally | Sreeni Yalamanchili